MOLECULAR EPIDEMIOLOGY TO UNDERSTAND THE SARS-CoV-2

EMERGENCE IN THE BRAZILIAN AMAZON REGION 2

- Mirleide Cordeiro dos Santos¹*, Edivaldo Costa Sousa Junior¹*, Jessylene de Almeida 3
- Ferreira¹*, Sandro Patroca da Silva², Michel Platini Caldas de Souza², Jedson Ferreira 4
- Cardoso², Amanda Mendes Silva¹, Luana Soares Barbagelata¹, Wanderley Dias das 5
- Chagas Junior¹, James Lima Ferreira¹, Edna Maria Acunã de Souza¹, Patrícia Louise 6
- Araújo Vilaça¹, Jainara Cristina dos Santos Alves², Michelle Carvalho de Abreu², 7
- Patrícia dos Santos Lobo², Fabíolla da Silva dos Santos², Alessandra Alves Polaro 8
- Lima², Camila de Marco Bragagnolo², Luana da Silva Soares², Patrícia Sousa Moraes 9
- de Almeida², Darleise de Souza Oliveira², Carolina Koury Nassar Amorim², Iran Barros 10
- Costa², Dielle Monteiro Teixeira², Edvaldo Tavares da Penha Júnior², Delana Andreza 11
- Melo Bezerra², Jones Anderson Monteiro Sigueira², Fernando Neto Tavares², Felipe 12
- Bonfim Freitas², Janete Taynã Nascimento Rodrigues³, Janaína Mazaro³, Andreia 13
- Santos Costa⁴, Márcia Socorro Pereira Cavalcante⁴, Marineide Souza da Silva⁵,
- 14
- Guilherme Alfredo Novelino Araújo⁵, Ilvanete Almeida da Silva⁶, Gleissy Adriane 15
- Lima Borges⁶, Lídio Gonçalves de Lima⁷, Hivylla Lorrana dos Santos Ferreira⁷, 16
- Miriam Teresinha Furlam Prando Livorati⁹, André Luiz de Abreu⁹, Arnaldo Correia de 17
- Medeiros⁹, Hugo Reis Resque², Rita Catarina Medeiros Sousa⁸, Giselle Maria Rachid 18
- Viana². 19

- 20 *Correspondent authors
- 21 Mirleide Cordeiro dos Santos – mirleidesantos@iec.gov.br
- 22 Edivaldo Costa Sousa Junior - costajr.013@gmail.com
- Jessylene de Almeida Ferreira jessylene_almeida@hotmail.com 23
- 24 **Affiliations**
- 25 ¹Laboratory of Respiratory Viruses, Evandro Chagas Institute (IEC), National Influenza Center (NIC) for
- the World Health Organization (WHO), Health Surveillance Office and Brazilian Health Ministry, 26
- 27 Ananindeua, Pará, Brazil.
- ²Virology section, Evandro Chagas Institute (IEC), Health Surveillance Office and Brazilian Health 28
- 29 Ministry, Ananindeua, Pará, Brazil.
- ³Laboratório Central de Saúde Pública do Acre (Central Laboratory of Public Health of Acre). 30
- 31 (LACEN-AC) Rio Branco, AC, Brazil.
- 32 ⁴Laboratório Central de Saúde Pública do Amapá – (Central Laboratory of Public Health of Amapá).
- 33 (LACEN-AP). Macapá, AP, Brazil.
 - NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

- ⁵Laboratório Central de Saúde Pública do Amazonas (Central Laboratory of Public Health of
- 35 Amazonas). (LACEN-AM). Manaus, AM, Brazil.
- 36 ⁶Laboratório Central de Saúde Pública do Pará (Central Laboratory of Public Health of Pará). (LACEN-
- PA). Belém, PA, Brazil.
- ⁷Laboratório Central de Saúde Pública do Maranhão (Central Laboratory of Public Health of
- 39 Maranhão). (LACEN-MA). São Luís, MA, Brazil.
- 40 ⁸ Virology Postgraduate Program, Evandro Chagas Institute, Para, Brazil
- 41 ⁹Secretaria de Vigilância em Saúde, Ministério da Saúde (Health Surveillance Office, Health Ministry).
- 42 Brasília, DF, Brazil.

43

44

61

62

63

64

65

66

67

68

69

70

71

72

73

74

ABSTRACT

- The COVID-19 pandemic in Brazil has demonstrated an important public health impact,
- as has been observed in the world. In Brazil, the Amazon Region contributed with a
- 47 large number of cases of COVID-19, especially in the beginning of the circulation of
- 48 SARS-CoV-2 in the country. Thus, we describe the epidemiological profile of COVID-
- 49 19 and the genetic diversity of SARS-CoV-2 strains circulating in the Amazon Region.
- 50 We observe an extensive spread of virus in this Brazilian site. The data on sex, age and
- 51 symptoms presented by the investigated individuals were similar to what has been
- 52 observed worldwide. The genomic analysis of the viruses revealed important amino
- 53 acid changes, including the D614G and the I33T in Spike and ORF6 proteins,
- respectively. The latter found in strains originating in Brazil. The phylogenetic analyzes
- demonstrated the circulation of the lineages B.1 and B.1.1, whose circulation in Brazil
- 56 has already been previous reported. Our data reveals molecular epidemiology of SARS-
- 57 CoV-2 in the Amazon Region. These findings also reinforce the importance of 58 continuous genomic surveillance this virus with the aim of providing accurate and
- 59 updated data to understand and map the transmission network of this agent in order to
- subsidize operational decisions in public health.
 - Keywords: SARS-CoV-2; COVID-19; Amazon Region; Brazil.

INTRODUCTION

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a newly discovered *Betacoronavirus*, now recognized as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)^{1,2}, and is responsible for one of the most significant pandemics in this century, causing millions of cases and high rates of hospitalizations and deaths^{3,4}.

In South America, Brazil holds the first place of infected individuals, with 3,761,391 diagnosed cases and, out of these, approximately 118,649 Brazilians have lost their lives due to COVID-19³. To this end, the Amazon region has effectively contributed to the number of 760,394 infected patients and 19.358 deaths (Update August 28th2020)⁵ with some of the states in this region presenting the worst scenario of

cases at the beginning of the pandemic in Brazil with high rates of occupancy in intensive care units (ICU) and deaths. Most persons with COVID-19 experience mild to moderate respiratory symptoms and recover⁶. On the other hand, individuals with underlying medical conditions, such as cardiovascular disease, diabetes, chronic respiratory diseases and cancer are more likely to be severely and possibly in need of intensive care 6,7 .

In addition to epidemiological information, the SARS-CoV-2 genomic data, as well as evolution datasets to quantify the impact of non-pharmaceutical interventions (NPIs) in virus spatiotemporal spread, are under much investigation, and until then it has been shown that this virus has diversified into several phylogenetic strains⁸, marked by different punctual mutations that reflect ongoing transmission currents⁹.

In view of the above, investigations aimed at evaluating the circulation dynamics, genetics and evolutionary characteristics of SARS-CoV-2 are of substantial importance for the global surveillance of this virus and, consequently, will provide a better understanding of the virus, the disease it causes and its circulation, providing relevant information for the development of new therapeutic and control strategies and prevention of infections by the new coronavirus. To this end, we combine genetics and epidemiological data to investigate the genetic diversity, evolution and epidemiology of SARS-CoV-2 in the Amazon region.

RESULTS

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

Epidemiological data

In the Brazilian Amazon region, 8,203 samples were analyzed and 4,400 of which (53.64%) were positive for SARS-CoV-2. The frequency of detection within the region is shown in figure 1. As for circulation, the highest rate was in epidemiological weeks (EW) 17, 18, 19 and 21, with the highest peak in EW 18 (figure 2).

Figure 1- Distribution of SARS-CoV-2 cases in the Amazon region. Total number of samples studied = 8,203.





Figure 2- Distribution of SARS-CoV-2 cases according to the epidemiological week.



Amongst the 4,400 SARS-CoV-2 positive cases, 214 did not contain age information. In this regard, the distribution of positive samples by age group has demonstrated that the highest frequency of positivity has occurred in the adult population amongst the over 20 age groups; the average age was 47 (figure 3). Regarding sex, 2,273 (51.57%) are female and 2,116 are male (56.04%) and 11 (0.25%) did not inform it. Fever (63.11%) was the most common symptom amongst patients, followed by cough (60.70%), dyspnoea (39.52%) and sore throat (39.45%) (figure 4).

Figure 3 - Absolute and relative frequency of positive and negative cases for SARS-CoV-2, by sex and age group.






Figure 4- Description of symptoms and signs among positive cases for COVID-19.



Amidst the confirmed cases of COVID-19 by molecular assay, it was observed that the detection range varied between the 1st and the 42nd day after the onset of symptoms, being the fifth day (62.22%) the best collection day for detection by RT-qPCR after the onset of symptoms (figure 5).

Figure 5 - Positivity for SARS-CoV-2 regarding disease duration.




NGS sequencing

Thirty-three (33) samples were successfully sequenced from the states of Acre (1), Amapá (11), Maranhão (8), Pará (11), Paraíba (1) and Rio Grande do Norte (1). These samples were analyzed and showed an average of 22,594,487 reads per sequenced sample, ranging from 1,476,498 to 50,601,712 reads (supplementary material 1).

Pre-processing data

After the trimming process of regions with low quality, removal of the adapters and reads smaller than 40 bp, these samples had presented an average of 18,207,316 reads per sample, extending from 971,498 to 42,083,456 reads and then were used for assembly by De Novo and Reference Mapping (figure 6 and supplementary material 1).

Figure 6 - Number of reads before and after pre-processing. The reads with length less than 40 bp and quality less than Phread 20 were removed.



Genome Assembly (De Novo and Reference Mapping)

For the genomic assembly process, the assembly was first done via the De Novo method, which has generated an average of 364,488 contigs per sample, extending from 3,964 to 1,816,455 contigs. As for the minimum size of the generated contigs is 200 bp, all the sequences under this length were discarded, for there is no variation in this item. The average of the maximum length of the contigs was 44,130 bp, extending from 4,574 bp to 312,642 bp. The generated N50 lengths were on average 409 bp, ranging from 344 bp to 618 bp (supplementary material 1).

For reference mapping assemblies, the average of reads mapped was 479,937 reads, extending from 11,935 to 3,087,036 reads per sample, leading to an average coverage of 3,007x, extending from 115x to 36,460x (figure 7 and supplementary material 1). All genomes had 38% GC content. There is no variation in this regard. All SARS-CoV-2 genomes were assembled almost entirely during assembly by De Novo, with only the ends needing editing, assembled via reference mapping and later sequence edition.

Phylogenetic Analysis and Mutation analysis

The genomes obtained were aligned with the reference strains deposited in GISAID, showing an identity of 99.98% (supplementary material 2). The analysis of the SARS-CoV-2 genome found revealed 62 nucleotide changes in 12 genes leading to 32 amino acid changes in 7 proteins (supplementary material 3).

The phylogenetic analysis reveals that isolates from present study clustering in three major clades in B.1 (one clade) and B.1.1 (two clades), with moderate statistical values of 70-89%. These clades are characterized by the presence of mutations S:D614G (B.1 and B.1.1) and substitutions in protein N (N:R203K and N:G204R) that classifies the lineage B.1.1 (Figure 08).

Figure 7 - Coverage plot by sample sequenced in the present study.

170







Figure 8 - SARS-CoV-2 complete genome phylogenetic tree (ML) with 1000 bootstraps, using GTR evolution model for nucleotide substitutions.



173

DISCUSSION

In Brazil, the first case of COVID-19 was detected in the state of São Paulo on February 26, 2020. In the Brazilian Amazon Region, the first detection has occurred in the state of Manaus on March 13, 2020 and, in that month, the Brazilian Health Ministry had already reported community transmission in the country, as well as a pandemic status by the World Health Organization (WHO). After the first detection of SARS-CoV-2 in this Brazilian site, an extensive spread of this virus was observed in the region, demonstrating, in the present study, a detection frequency of 53.64% showing a critical adaptation and circulation of SARS-CoV-2 in this tropical region. The most active circulation of SARS-CoV-2 has occurred mainly in April and May, in EW 17, 18, 19 and 21, which coincides with the Amazonian winter season.

The detection of SARS-CoV-2 has occurred in all age groups. However, the highest frequency has occurred in adults and the elderly, as described in the world population^{10–13}. The low frequency of SARS-CoV-2 in children and teenagers under 20, verified in the present study, has been associated with reduced susceptibility and less likelihood to infection or a combination of both, compared to adults^{14–16}.

As for sex, similar to what has been reported by literature, the frequency amongst men was slightly higher than in women^{17,18}. Estrogen, the main female sex hormone, plays a possible protective role in COVID-19, activating the immune response, and directly suppressing SARS-CoV-2 replication^{19,20}. Indeed, estrogen inhibits the activity or expression of different components of the renin-angiotensin system. Particularly, estrogen can upregulate ACE2 expression^{21,22}. Regarding the clinical analysis presented by the investigated patients, the most described symptoms were fever, cough, sore throat and dyspnoea, respectively, associated or not, commonly reported amongst respiratory infections, as well as in COVID-19^{10,11,23,24}. However, unlike other respiratory infections, in COVID-19 anosmia and dysgeusia have been frequently reported^{25–29}, as described amongst patients in the study region. After the onset of symptoms, the period of greatest detection of SARS-CoV-2 by RT-qPCR has occurred on the fifth day, similarly to what has been described in other studies³⁰.

The genomic analysis of the viruses found revealed that 61 nucleotide mutations were found in the entire genome when compared to the reference genome, and, out of these, 16 led to amino acid changes, with emphasis on the substitutions in S and N proteins that have a structural role and ORF6, a non-structural protein not yet characterized ^{31,32}.

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238 239

240

241

242

243

244

Amongst the alterations in the Spike protein that plays a role in binding to the human ACE2 receptor and is also the main antigenic target, it was found the D614G substitution that is described as a factor that antigenically favors the virus, giving it a higher capacity to infection³³ and has been used as a genetic marker for strains of the Blineage (Pangolin Classification) which has become the largest circulating group worldwide³⁴. Also, it was verified the V1176F mutation described in the literature³⁵ and used as a genetic marker for samples circulating in Brazil (https://www.gisaid.org), but no antigenic advantage has yet been attributed.

Regarding the N protein plays a role in folding viral genetic material and has been used as a marker for samples from Europe, it was verified R203K, G204R and I292T amino acidic substitutions. However, their molecular roles are still unclear^{36,37}. The change I33T in ORF6, a non-structural protein, has been observed in samples originating in Brazil and that circulate in South America³⁸.

The phylogenetic analysis revealed that the samples of this study have formed three distinct groups that cluster with the phylogenetic lineages B.1 and B.1.1 that have samples already sequenced from Brazil³⁹. Within clade B.1, only two samples from Pará were clustering with samples from Europe. In clade B.1.1, it was possible to observe the formation of two distinct groups divided by the I33T ORF6 and V1176F S protein substitutions. These two mutations have been observed to divide the two main strains of SARS-CoV-2 circulating in Brazil³⁴. Since its worldwide circulation on December 2019⁴⁰, the SARS-CoV-2 genome has changed wherever it arrives⁴¹, which may mean a likely adaptation to the population⁴².

In this study, we did not yet had the chance to analyze how SARSCoV-2 became established across the Amazon region and to associate the finding lineages with the population movements, that is, to relate to the proportion of within and between state measured virus movements. Another relevant issue is that the B.1 and B.1.1 lineages from the Amazon region were quite similar, making it difficult to trace with precision the origin of these strains in the study site.

In conclusion, this study reveals that the highest SARS-CoV-2 circulation has reached its peak in epidemiological week 18. The distribution of positive samples by age group has demonstrated that the median age was 47, with men being the main affected gender and there was a spectrum of symptoms composed of fever, cough, dyspnoea and sore throat. Furthermore, this investigation supports the evidence for the existence of two main lineages (B.1 and B.1.1) associated with genomic epidemiology

of SARS-CoV-2 in the Amazon region. Thus, genomic surveillance must be continuously adopted to be able to offer accurate and quality data to understand where this virus emerged from, and map the transmission network to improve operational decisions in public health.

METHODS

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

Samples and ethical aspects

The Laboratory of Respiratory Viruses of the Evandro Chagas Institute (LVR-IEC), located in the Amazon region, works with the World Health Organization (WHO) as a National Influenza Center (NIC) for the surveillance of influenza and other respiratory viruses, amongst them, the SARS-CoV-2. Thus, this laboratory has received 8,203 clinical specimens from patients of both sexes and in different age groups (zero to 111 years old) between February 27th, 2020 to July 1st, 2020 for the diagnosis of SARS-CoV-2 from the states of Acre, Amapá, Amazonas, Ceará, Maranhão, Pará, Paraíba, Pernambuco, Rio Grande Norte and Roraima. The clinical specimens collected and used for molecular diagnosis and viral genetic analysis were nasopharyngeal swabs plus throat swabs, nasopharyngeal aspirate and sputum. This study was approved by Evandro Chagas Institute Ethical Committee (34931820.0.0000.0019).

Extraction and Detection by RT-qPCR of viral nucleic acid

The viral RNA was extracted manually using the QIAamp® Viral RNA Mini Kit (QIAGEN, Hilden, Germany) following the manufacturer's guidelines. The detection of the viral genome by RT-qPCR was performed with the Molecular Kit SARS-CoV-2 (E/RP) Biomanguinhos (Biomanguinhos, Rio de Janeiro, Brazil), according to the protocol described by Corman et al (2020)⁴⁵.

The amplification reaction was conducted sequentially in the following steps: reverse transcription at 50°C for 15 minutes, followed by transcriptase inactivation and activation of Taq DNA polymerase at 95 ° C for 2 minutes, polymerase chain reaction at 95°C for 15 seconds in 45 cycles, extension and annealing at 55 °C for 30 seconds. At the end of the amplification, all clinical samples should have reaction sigmoid curves for the targets that cross the limit line (cycle threshold - Ct) equal to or before 40 cycles. Positive and negative controls were included in each reaction.

Epidemiological analysis

Graphs of epidemiological data (age, sex, state, signs and symptoms) and circulation were performed with support by the LVR-IEC database and the Microsoft Office Excel program. The data were inspected, visualized and plotted using the R programming language script⁴³ together with the libraries ggplot2⁴⁴, geobr⁴⁵, pipeR⁴⁶, readr⁴⁷, lubridate, fmsb⁴⁸, plyr⁴⁹, scales⁵⁰, viridis⁵¹ and hrbrthemes⁵². By international convention, epidemiological weeks were counted from Sunday to Saturday, considering the sample collection date.

Sample selection for sequencing

The selection of strains for sequencing the viral genome was conducted so that there was geographical and temporal representativeness. In this aspect, the date of collection and the respective epidemiological week of the sample of each state of origin were considered to reach the minimum representation of each federated unit per epidemiological week. In addition, in order to obtain the highest amount of viral RNA and, thus, a greater chance of success in sequencing, samples that showed $Ct \le 20$ in the RT-qPCR for SARS-CoV-2 were selected.

Library construction and sequencing

The total RNA was converted to complementary DNA (cDNA) using the cDNA Synthesis System Kit and 400 μ M of random primers, following the manufacturer's procedure. The reaction solution was purified with the Agencourt AMPure XP Reagent. The cDNA library was prepared and sequenced using the methodology described in the Nextera XT DNA Library Preparation Kit on a NextSeq (Illumina, Inc) platform by paired-end methodology with 300 cycles (2x150 reads), in the Evandro Chagas Institute, Brazil Ministry of Health.

Data pre-processing

The data were evaluated for their quality regions. The adapters sequences reads with a quality lower than Phred 20 and reads with less than 40 bp size, were removed using Trimmommatic⁵³. The processed reads were visualized with FastQC⁵⁴. For Trimmomatic, we have used the following parameters: LEADING:3 TRAILING:3 MINLEN:40

Genome Assembly (De Novo and Reference Mapping)

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

For this step, the reads validated based on quality trimming were used to assembly the SARS-CoV-2 genomes. The De Novo assembly was performed using the Megahit v.1.1.4-2⁵⁵ and for Reference Mapping we have used the software Bowtie2⁵⁶ and Geneious Prime, where the respective coverage, gaps and final size of the genome were analyzed. For genome assembly, all programs were performed with default parameters.

Taxonomic annotation and submission to GISAID

The generated de novo contigs were compared using the Blastx tool⁵⁷ implemented in Diamond v.0.9.33⁵⁸, against the RefSeq database (NCBI's Protein Reference Sequences Database), which is a database of cured protein sequences and which provides a high level of annotation, such as the description of the function of a protein, its domain structure, post-translational modifications, where a statistical value (e-value) of 0.0001 was considered.

The viral genome annotation was performed automatically using the Geneious Prime software (Biomatters, Ltd., New Zealand, 2019) and cured manually by comparing the starts and stop codons, as well as the sizes of the genes. These genome sequences subsequently submitted to the **GISAID** were database (https://www.gisaid.org/) under accession numbers EPI ISL 450873-450874, EPI ISL 458138-EPI ISL 458149 and EPI ISL 524783-EPI ISL 524801.

Phylogenetic Analysis and Mutation analysis

The genomes sequences were aligned with other genomes from all the world using the Mafft v.7.471⁵⁹. For phylogenetic analysis the software RaXML⁶⁰ with 1000 bootstraps was used as statistical support, using GTR as a nucleotide substitution model. The genomes obtained were compared to the reference strain (NC_045512) by in house python script that compares each base of the entire genome and gives us a mutation list.

REFERENCES

- 342 1. Gorbalenya, A. E. et al. The species Severe acute respiratory syndrome-related
- coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. 343
- *Microbiol.* **5**, 536–544 (2020). 344
- 2. Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel 345
- coronavirus: implications for virus origins and receptor binding. Lancet 395, 346
- 347 565-574 (2020).
- World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. 348 3.
- 349 WHO Coronavirus Disease (COVID-19) Dashboard (2020).
- 4. World Health Organization. Statement on the second meeting of the International 350
- Health Regulations (2005) Emergency Committee regarding the outbreak of 351
- novel coronavirus (2019-nCoV). https://www.who.int/news-room/detail/30-01-352
- 2020-statement-on-the-second-meeting-of-the-international-health-regulations-353
- (2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-354
- 355 (2019-ncov) (2020).
- Ministry of health. COVID-19 in Brazil. 356 5.
- http://susanalitico.saude.gov.br/#/dashboard/(2020). 357
- 358 6. Huang, C. et al. Clinical features of patients infected with 2019 novel
- coronavirus in Wuhan, China. Lancet 395, 497-506 (2020). 359
- Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients 7. 360
- 361 with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395,
- 1054-1062 (2020). 362
- 363 8. Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 to assist
- genomic epidemiology. bioRxiv 2020.04.17.046086 (2020). 364
- doi:10.1101/2020.04.17.046086 365
- 9. Stefanelli, P. et al. Whole genome and phylogenetic analysis of two SARSCoV-2 366
- strains isolated in Italy in January and February 2020: Additional clues on 367
- 368 multiple introductions and further circulation in Europe. Eurosurveillance 25, 1—
- 369 5 (2020).
- 370 10. Guan, W. et al. Clinical characteristics of coronavirus disease 2019 in China. N.
- Engl. J. Med. 382, 1708-1720 (2020). 371
- 11. Jiang, F. et al. Review of the Clinical Characteristics of Coronavirus Disease 372
- 2019 (COVID-19). J. Gen. Intern. Med. 35, 1545–1549 (2020). 373
- 374 12. Shahid, Z. et al. COVID-19 and Older Adults: What We Know. J. Am. Geriatr.
- Soc. **68**, 926–929 (2020). 375
- 13. Nikolich-Zugich, J. et al. SARS-CoV-2 and COVID-19 in older adults: what we 376
- may expect regarding pathogenesis, immune responses, and outcomes. 377
- GeroScience 42, 505–514 (2020). 378
- 14. Davies, N. G. et al. Age-dependent effects in the transmission and control of 379
- COVID-19 epidemics. Nat. Med. (2020). doi:10.1038/s41591-020-0962-9 380

- 15. Mantovani, A. et al. Coronavirus disease 2019 (COVID-19) in children and/or 381 adolescents: a meta-analysis. Pediatr. Res. 2019, (2020). 382
- 16. Ludvigsson, J. F. Systematic review of COVID-19 in children shows milder 383 cases and a better prognosis than adults. Acta Paediatr. Int. J. Paediatr. 109, 384 1088–1095 (2020). 385
- Li, L. quan et al. COVID-19 patients' clinical characteristics, discharge rate, and 386 17. 387 fatality rate of meta-analysis. J. Med. Virol. 92, 577–583 (2020).
- 18. Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R. & Klein, S. L. 388 389 Impact of sex and gender on COVID-19 outcomes in Europe. Biol. Sex Differ. 390 **11**, 1–13 (2020).
- 391 19. Channappanavar, R. et al. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. J. Immunol. 198, 4046–4053 392 (2017).393
- Scully, E. P., Haverfield, J., Ursin, R. L., Tannenbaum, C. & Klein, S. L. 394 20. 395 Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat. Rev. Immunol. (2020). doi:10.1038/s41577-020-0348-8 396
- 21. Bukowska, A. et al. Protective regulation of the ACE2/ACE gene expression by 397 estrogen in human atrial tissue from elderly men. Exp. Biol. Med. 242, 1412– 398 399 1423 (2017).
- 22. Scully, E. P., Haverfield, J., Ursin, R. L., Tannenbaum, C. & Klein, S. L. 400 401 Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat. Rev. Immunol. (2020). doi:10.1038/s41577-020-0348-8 402
- 403 23. Rodríguez-Cola, M. et al. Clinical features of coronavirus disease 2019 (COVID-404 19) in a cohort of patients with disability due to spinal cord injury. Spinal Cord Ser. Cases 6, (2020). 405
- Ge, H. et al. The epidemiology and clinical information about COVID-19. Eur. J. 406 24. Clin. Microbiol. Infect. Dis. 39, 1011–1019 (2020). 407
- 408 25. Vaira, L. A., Salzano, G., Deiana, G. & De Riu, G. Anosmia and Ageusia: Common Findings in COVID-19 Patients. *Laryngoscope* **130**, 1787 (2020). 409
- 410 26. Vaira, L. A., Salzano, G., Fois, A. G., Piombino, P. & De Riu, G. Potential pathogenesis of ageusia and anosmia in COVID-19 patients. Int. Forum Allergy 411 Rhinol. **00**, 1–2 (2020). 412
- 27. Russell, B. et al. Anosmia and ageusia are emerging as symptoms in patients 413 with COVID-19: What does the current evidence say? *Ecancermedicalscience* 414 415 **14**, 9–10 (2020).
- Klopfenstein, T. et al. Features of anosmia in COVID-19. Med. Mal. Infect. 4–7 416 28. 417 (2020). doi:10.1016/j.medmal.2020.04.006
- 29. Whittaker, A., Anson, M. & Harky, A. Neurological Manifestations of COVID-418 419 19: A systematic review and current update. Acta Neurol. Scand. 142, 14–22 (2020).420

- 30. Rodríguez-Cola, M. et al. Clinical features of coronavirus disease 2019 (COVID-421
- 19) in a cohort of patients with disability due to spinal cord injury. Spinal Cord 422
- 423 Ser. Cases 6, (2020).
- 31. Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for 424
- drug repurposing. Nature 583, (2020). 425
- da Silva, S. J. R., da Silva, C. T. A., Mendes, R. P. G. & Pena, L. Role of 426 32.
- 427 Nonstructural Proteins in the Pathogenesis of SARS-CoV-2. J. Med. Virol. 3–5
- (2020). doi:10.1002/jmv.25858 428
- 429 33. Korber, B. et al. Tracking changes in SARS-CoV-2 Spike: evidence that D614G
- increases infectivity of the COVID-19 virus. Cell (2020). 430
- doi:10.1016/j.cell.2020.06.043 431
- 34. Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data – 432
- from vision to reality. Eurosurveillance 22, 2–4 (2017). 433
- Gonçalves, R. L. et al. SARS-CoV-2 mutations and where to find them: An in 434 35.
- silico perspective of structural changes and antigenicity of the Spike protein. 435
- bioRxiv 3, 2020.05.21.108563 (2020). 436
- Yin, C. Genotyping coronavirus SARS-CoV-2: methods and implications. 437 36.
- Genomics 19, 1–12 (2020). 438
- 37. Castillo, A. E. et al. Phylogenetic analysis of the first four SARS-CoV-2 cases in 439
- Chile. J. Med. Virol. 1–5 (2020). doi:10.1002/jmv.25797 440
- 441 38. Resende, P. C. et al. Genomic surveillance of SARS-CoV-2 reveals community
- transmission of a major lineage during the early pandemic phase in Brazil. 442
- bioRxiv 2020.06.17.158006 (2020). doi:10.1101/2020.06.17.158006 443
- 39. 444 Candido, D. S. et al. Evolution and epidemic spread of SARS-Cov-2 in Brazil.
- 445 Science (80-.). 21, 1-9 (2020).
- 40. Riou, J. & Althaus, C. L. Pattern of early human-to-human transmission of 446
- Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. 447
- 448 *Eurosurveillance* **25**, 1–5 (2020).
- 449 41. Pachetti, M. et al. Emerging SARS-CoV-2 mutation hot spots include a novel
- RNA-dependent-RNA polymerase variant. J. Transl. Med. 18, 1–9 (2020). 450
- 42. Cao, Y. et al. Comparative genetic analysis of the novel coronavirus (2019-451
- 452 nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 6, 4–7
- (2020).453
- R Foundation for Statistical Computing. R Core Team (2018). R: A language and 454 43.
- environment for statistical computing. (2018). 455
- 456 44. Wickham, H. ggplot2: Elegant Graphics for Data Analysis. (2009).
- 45. Pereira, R.H.M.; Gonçalves, C. N. geobr: Loads Shapefiles of Official Spatial 457
- 458 Data Sets of Brazil. GitHub repository. (2019).
- 459 46. Ren, K. pipeR: Multi-Paradigm Pipeline Implementation. R package version

perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

- 460 0.6.1.3. (2016).
- 461 47. Hadley Wickham, J. H. and R. F. readr: Read Rectangular Text Data. R package version 1.3.1. (2018).
- 48. Nakazawa, M. fmsb: Functions for Medical Statistics Book with some
- Demographic Data. R package version 0.7.0. https://CRAN.R-
- project.org/package=fmsb (2019).
- 466 49. Wickham, H. The Split-Apply-Combine Strategy for Data Analysis. Journal of
 467 Statistical Software, 40(1), 1-29. (2011).
- 468 50. Seidel, H. W. and D. scales: Scale Functions for Visualization. R package version 1.1.1. (2020).
- 51. Simon Garnier. viridis: Default Color Maps from 'matplotlib'. R package version 0.5.1. (2018).
- 52. Bob Rudis. hrbrthemes: Additional Themes, Theme Components and Utilities for 'ggplot2'. R package version 0.8.0. 2020
- 474 53. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. *Bioinformatics* **30**, 2114–2120 (2014).
- 476 54. Andrews, S. FastQC: a quality control tool for high throughput sequence data. 477 http://www.bioinformatics.babraham.ac.uk/project (2010).
- 478 55. Li, D., Liu, C. M., Luo, R., Sadakane, K. & Lam, T. W. MEGAHIT: An ultrafast single-node solution for large and complex metagenomics assembly via 480 succinct de Bruijn graph. *Bioinformatics* **31**, 1674–1676 (2015).
- Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.*
- **10**, (2009).

491

- 484 57. Madden, T. & Coulouris, G. BLAST+ User Manual. *Ncbi* 1–64 (2008).
- 485 58. Buchfink, B., Xie, C. & Huson, D. H. Fast and sensitive protein alignment using DIAMOND. *Nat. Methods* **12**, 59–60 (2015).
- Katoh, K. & Toh, H. Parallelization of the MAFFT multiple sequence alignment program. *Bioinformatics* **26**, 1899–900 (2010).
- 489 60. Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-490 analysis of large phylogenies. *Bioinformatics* **30**, 1312–3 (2014).

perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

Acknowledgements

- The authors would like to thank all the professionals who worked bravely to deal with
- 495 this pandemic, especially in the Amazon. We thank the Evandro Chagas Institute, where
- 496 the development of the research was carried out with great contribution from the
- 497 virology team. We would also like to thank the General Coordination of Laboratories
- 498 (CGLab) of the Ministry of Health (MS), States of the Brazilian Central Laboratory
- 499 (LACENs), and local surveillance teams for the partnership in viral surveillance in
- 500 Brazil.

501

502

512

513

515

493

Author contributions

- MCS, HRR, RCMS and GMRV coordinated the study; ECSJ, JAF, AMS, SPS, MPCS
- and JFC performed the sequencing and genomic analysis of SARS-CoV-2 strains; LSB,
- 505 WDCJ, AMS and JAF performed the detection of SARS-CoV-2 by RT-qPCR; AMS,
- JLF, EMAS, CKNA and DSO received and checked the samples; PLAV, JCSA, MCA,
- PSL, FSS, AAPL, CMB, LSS and PSMA performed the registration of epidemiological
- data in a database and assisted in the release of results; IBC, DMT, ETPJ, DAMB,
- JAMS, FNT and FBF performed the extraction of the viral genome; MSS, GAN, IAS,
- 510 GALB, LGL, HLSF collected the samples; MTFPL, ALA and ACM assisted with
- technical support through the viral surveillance network in Brazil.

Additional Information

- The authors declare that they have no conflicting interests.
- Figure 1 Distribution of SARS-CoV-2 cases in the Amazon region. Total number of
- samples studied = 8,203.
- Figure 2 Distribution of SARS-CoV-2 cases according to the epidemiological week.
- 519 Figure 3 Absolute and relative frequency of positive and negative cases for SARS-
- 520 CoV-2, by sex and age group.
- Figure 4 Description of symptoms and signs among positive cases for COVID-19.
- **Figure 5** Positivity for SARS-CoV-2 regarding disease duration.
- Figure 6 Number of reads before and after pre-processing. The reads with length less
- than 40 bp and quality less than Phread 20 were removed.

- Figure 7 Coverage plot by sample sequenced in the present study. 525
- 526 Figure 8 - SARS-CoV-2 complete genome phylogenetic tree (ML) with 1000
- bootstraps, using GTR evolution model for nucleotide substitutions. 527